Zafgen Inc (ZFGN) Expected to Post Earnings of -$0.43 Per Share
Equities research analysts forecast that Zafgen Inc (NASDAQ:ZFGN) will post earnings per share (EPS) of ($0.43) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Zafgen’s earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.39). Zafgen posted earnings per share of ($0.48) in the same quarter last year, which indicates a positive year-over-year growth rate of 10.4%. The company is scheduled to report its next quarterly earnings results on Tuesday, March 5th.
On average, analysts expect that Zafgen will report full-year earnings of ($1.96) per share for the current fiscal year, with EPS estimates ranging from ($2.01) to ($1.91). For the next financial year, analysts forecast that the business will post earnings of ($1.76) per share, with EPS estimates ranging from ($2.23) to ($1.28). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Zafgen.
Zafgen (NASDAQ:ZFGN) last released its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.04.
A number of institutional investors have recently added to or reduced their stakes in the business. Voya Investment Management LLC acquired a new position in shares of Zafgen during the 2nd quarter worth $104,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Zafgen during the 2nd quarter worth about $110,000. Trexquant Investment LP acquired a new stake in Zafgen in the 2nd quarter valued at about $117,000. Private Advisor Group LLC acquired a new stake in shares of Zafgen during the 2nd quarter worth approximately $153,000. Finally, Wells Fargo & Company MN grew its position in shares of Zafgen by 428.7% during the 3rd quarter. Wells Fargo & Company MN now owns 14,783 shares of the biopharmaceutical company’s stock worth $173,000 after buying an additional 11,987 shares during the period. Hedge funds and other institutional investors own 81.55% of the company’s stock.
Shares of NASDAQ:ZFGN traded up $0.02 during midday trading on Monday, hitting $5.02. 4,260 shares of the company’s stock traded hands, compared to its average volume of 537,182. The company has a current ratio of 11.78, a quick ratio of 11.78 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $185.09 million, a price-to-earnings ratio of -2.66 and a beta of -0.35. Zafgen has a twelve month low of $3.57 and a twelve month high of $12.35.
Zafgen Company Profile
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Featured Article: What is a bull market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.